Prescription Pattern of Tofacitinib for Alopecia Areata Among Dermatologists in Saudi Arabia: A Cross-Sectional Study

    June 2023 in “ Cureus ”
    Abdulaziz S Alsuhibani, Raghad Alharthi, Saba AlSuhaymi … Mohammad Almohideb
    Studysummary This study found that 23.2% of surveyed dermatologists in Saudi Arabia prescribe Tofacitinib for alopecia areata, with 72.4% reporting its effectiveness, while 47.7% cited unavailability as the main reason for not prescribing.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on cureus.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Case Report of Novel Combination of Anthralin and Calcipotriene Leading to Trichologic Response in Alopecia Areata JAAD case reports · 2019
    2. JAK Inhibitors and Alopecia Areata Lancet · 2019
    3. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    4. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016

    Related research 2

    1. Resistant Alopecia Areata Treated with Tofacitinib International Journal of Trichology · 2022
    2. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018